Connect your AI

Medifast MED Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Omada Health, Inc. Common StockOMDA

-$2K-100%

Lifevantage CorporationLFVN

-$3K—

Other financials

Income statement

Revenue$76.0M-34.3%

Gross profit$51.8M-38.6%

Operating income-$3.3M-161%

Net income-$2.1M-175%

EPS (diluted)-$0.19-171%

Balance sheet

Cash & equivalents$71.5M-22.0%

Total debt$16.1M+10.2%

Total equity$197.7M-6.3%

Total assets$252.0M-10.0%

Cash flow

Operating cash flow$260.0K-92.4%

CapEx$1.1M-28.0%

Free cash flow-$836.0K-144%

Valuation

Market cap$121.87M-17.4%

Enterprise value$66.44M+12.8%

P/S0.4×0.0×

Profitability

Gross margin70.1%-3.8pp

Operating margin-4.7%-7.0pp

Net margin-5.8%-8.1pp

FCF margin5%-9.3pp

Returns & leverage

Return on equity-9.8%-20.1pp

Debt / equity0.1×0.0×

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Medifast in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medifast's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Medifast's gain/loss on asset sales?: Medifast (MED) reported gain/loss on asset sales of -$63K in Q1 2026.
How has Medifast's gain/loss on asset sales changed year-over-year?: Medifast's gain/loss on asset sales increased by 83.7% year-over-year, from -$387K to -$63K.
What is the long-term trend for Medifast's gain/loss on asset sales?: Over 3 years (2021 to 2025), Medifast's gain/loss on asset sales has grown at a 782.2% compound annual growth rate (CAGR), from -$2K to -$1.37M.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.